Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Stage 2 and 3 Neurotrophic Keratitis Subjects

NCT04909450 is registered in ClinicalTrials.gov with Claris Biotherapeutics, Inc. as lead sponsor.

NCT NCT04909450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04909450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Stage 2 and 3 Neurotrophic Keratitis Subjects
Lead sponsor
Claris Biotherapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
August 24, 2021
Completion date
June 4, 2024
Enrollment
131 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

neurotrophic keratitis